Case Report: Voglibose-induced persistent leukopenia in a patient with type 2 diabetes
-
By
-
Jing-wen Guo
-
Jin-hong Yan
-
Li-shuang Chang
-
Shuang Cai
-
Ya-qiu Jiang
-
Fen-qin Chen
-
June 4, 2026
-
Clinical Scorecard: Case Study: Persistent Leukopenia Associated with Long-term Use of Voglibose in a Type 2 Diabetes Patient
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Potential drug-induced cytopenia from voglibose, though rare. |
| Target Population | |
| Care Setting | |
Key Highlights
- 71-year-old male with type 2 diabetes developed leukopenia over five years, despite various treatments.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
- Regular monitoring of white blood cell counts in patients on long-term voglibose, ideally every 3-6 months.
Risks
Patient & Prescribing Data
Voglibose may rarely induce chronic leukopenia; consider alternatives like acarbose, especially after ineffective treatments.
Clinical Best Practices
- Conduct thorough medication reviews in patients with unexplained cytopenia, involving pharmacists and hematologists.
Related Resources & Content
